Rafael (NYSE:RFL – Get Free Report) and Maui Land & Pineapple (NYSE:MLP – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.
Risk & Volatility
Rafael has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500. Comparatively, Maui Land & Pineapple has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500.
Valuation & Earnings
This table compares Rafael and Maui Land & Pineapple’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Maui Land & Pineapple||$20.96 million||12.32||$1.79 million||($0.55)||-23.91|
Insider and Institutional Ownership
16.9% of Rafael shares are held by institutional investors. Comparatively, 21.5% of Maui Land & Pineapple shares are held by institutional investors. 8.4% of Rafael shares are held by insiders. Comparatively, 65.0% of Maui Land & Pineapple shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This table compares Rafael and Maui Land & Pineapple’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Maui Land & Pineapple||-111.65%||-31.46%||-25.06%|
This is a summary of current recommendations and price targets for Rafael and Maui Land & Pineapple, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Maui Land & Pineapple||0||0||0||0||N/A|
Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), that is in Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
About Maui Land & Pineapple
Maui Land & Pineapple Company, Inc., together with its subsidiaries, develops, manages, and sells residential, resort, commercial, agricultural, and industrial real estate properties in the United States. It operates through Real Estate, Leasing, and Resort Amenities segments. The Real Estate segment is involved in the land planning and entitlement; and development and sale of its landholdings on Maui. The Leasing segment leases commercial, agricultural, and industrial land and properties; and licenses its registered trademarks and trade names, as well as provides stewardship and conservation services. This segment also manages ditches, reservoirs, and well systems that provide potable and non-potable water to West and Upcountry Maui areas. The Resort Amenities segment manages the operations of the Kapalua Club, a private non-equity club program that provides its members special programs, access, and other privileges at certain amenities at the Kapalua Resort. It owns approximately 22,000 acres of land on the island of Maui, Hawaii. Maui Land & Pineapple Company, Inc. was incorporated in 1909 and is based in Lahaina, Hawaii.
Receive News & Ratings for Rafael Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rafael and related companies with MarketBeat.com's FREE daily email newsletter.